Helicobacter pylori eradication therapy is effective in preventing gastric cancer, even in patients with advanced pre-neoplastic lesions (gastric atrophy and/or intestinal metaplasia). We must now focus on how to accomplish the goal of eliminating gastric cancer-related death worldwide; strategies for screening and treatment of gastric neoplasia (primary prevention) and post-treatment surveillance (secondary prevention) are discussed herein.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Efficacy and safety of ultraviolet C therapy for the eradication of Helicobacter pylori
BMC Gastroenterology Open Access 10 December 2025
-
Characterization of antibiotic resistance and biofilm formation in clinical Helicobacter pylori isolates from Ningxia, China
Scientific Reports Open Access 27 November 2025
-
Pyrosequencing analysis for rapid and accurate detection of clarithromycin resistance-associated mutations in Iranian Helicobacter pylori isolates
BMC Research Notes Open Access 06 July 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Uemura, N. et al. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 345, 784–789 (2001).
Ford, A. C. et al. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ 348, g3174 (2004).
Yoon, S. B. et al. Effect of Helicobacter pylori eradication on metachronous gastric cancer after endoscopic resection of gastric tumors: a meta-analysis. Helicobacter 19, 243–248 (2014).
Sugano, K. et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 64, 1353–1367 (2015).
Choi, I. J. et al. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N. Engl. J. Med. 378, 1085–1095 (2018).
Lee, Y. C. et al. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut 62, 676–682 (2013).
Tsuda, M. et al. Effect on Helicobacter pylori eradication therapy against gastric cancer in Japan. Helicobacter 22, e12415 (2017).
Vilaichone, R. K. et al. Extremely high prevalence of Helicobacter pylori infection in Bhutan. World J. Gastroenterol. 19, 2806–2810 (2013).
Kuo, Y. T. et al. Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 2, 707–715 (2017).
Rugge, M. et al. Gastritis staging in the endoscopic follow-up for the secondary prevention of gastric cancer: a 5-year prospective study of 1755 patients. Gut https://doi.org/10.1136/gutjnl-2017-314600 (2018).
Acknowledgements
The author acknowledges support from the US NIH National Institute of Diabetes and Digestive and Kidney Diseases (grant DK62813); the Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (grant 16H05191); and from the Japan Society for the Promotion of Science (Core-to-Core Program).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Additional information
Related links
GLOBOCAN 2012: http://globocan.iarc.fr/
Rights and permissions
About this article
Cite this article
Yamaoka, Y. How to eliminate gastric cancer-related death worldwide?. Nat Rev Clin Oncol 15, 407–408 (2018). https://doi.org/10.1038/s41571-018-0029-8
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41571-018-0029-8
This article is cited by
-
Efficacy and safety of ultraviolet C therapy for the eradication of Helicobacter pylori
BMC Gastroenterology (2025)
-
Characterization of antibiotic resistance and biofilm formation in clinical Helicobacter pylori isolates from Ningxia, China
Scientific Reports (2025)
-
Cloning, Expression, Purification and Biological Activity Analysis of Recombinant Helicobacter pylori FabI as a Drug Target
Molecular Biotechnology (2025)
-
Development and Evaluation of Novel Amoxicillin and Phytic Acid-Loaded Gastro-Retentive Mucoadhesive Pectin Microparticles for the Management of Helicobacter pylori Infections
Journal of Pharmaceutical Innovation (2024)
-
Pyrosequencing analysis for rapid and accurate detection of clarithromycin resistance-associated mutations in Iranian Helicobacter pylori isolates
BMC Research Notes (2023)
